Quantcast

Latest eye diseases Stories

2009-11-16 16:27:17

Determining what triggers the death of retinal cells, called photoreceptors, could hold the key to stopping blinding disorders caused by a wide range of eye diseases, Yale School of Medicine researchers report in the November journal Investigative Ophthalmology & Visual Science. Several blinding disorders are known to cause the breakdown of photoreceptors. Caroline Zeiss, associate professor of comparative medicine and ophthalmology at Yale School of Medicine, and her colleagues sought to...

2009-11-16 09:07:00

ST. LOUIS, Nov. 16 /PRNewswire/ -- It's a fact of life that eyes change with age, and baby boomers - Americans born between 1946 and 1964 - are at the stage when many are affected by vision problems. Despite the prevalence of Americans affected by these changes, a new survey from the American Optometric Association (AOA) shows a concerning lack of public knowledge and misunderstanding regarding age-related eye diseases and conditions. According to the AOA's American...

2009-09-24 10:25:00

NEW YORK, Sept. 24 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Advances in Ophthalmology: Markets in the Treatment of Eye Disorders and Corrective Vision, 2nd Edition http://www.reportlinker.com/p0132603/Advances-in-Ophthalmology-Markets-in-the-Treatment-of-Eye-Disorders-and-Corrective-Vision-2nd-Ediiton.html The information represented in this report is a comprehensive analysis of the eye care market globally with a special...

2009-09-14 06:00:00

TARRYTOWN, N.Y., Sept. 14 /PRNewswire-FirstCall/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the completion of patient enrollment in two randomized, double-masked, Phase 3 clinical trials evaluating VEGF Trap-Eye in the treatment of the neovascular form of age-related macular degeneration (wet AMD). In each study of the VIEW (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD) program, VEGF Trap-Eye is being evaluated for its effect on maintaining and...

2009-08-03 10:07:22

 A new class of antibody drugs may provide a powerful new tool for the treatment of eye diseases in children, but specialists need to be alert for the possibility of serious side effects, according to an editorial in the August Journal of AAPOS (American Association for Pediatric Ophthalmology and Strabismus), published by Elsevier.Dr. Robert L. Avery of Santa Barbara, Calif., discusses issues related to the use of antibodies against vascular endothelial growth factor (VEGF) in pediatric...

2009-07-31 01:25:00

TOKYO, July 31 /PRNewswire/ -- R-Tech Ueno, Ltd. announced on July 29 after discussing its R&D policy at a meeting of the board of directors held on the day and determined the R&D items as follows. The company intends to actively strengthen R&D in the ophthalmologic & dermatological fields that are its priority and exclusive areas, and promote relevant affiliation, etc. with external entities. 1. Development code UF-021 (eye diseases) The item in question is isopropyl...

2008-11-05 03:00:17

WALTHAM, Mass., Nov. 5, 2008 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended September 30, 2008 and presented an update on recent clinical and corporate progress. "OXiGENE today is a leader in the field of vascular disrupting agents, an important new class of therapeutics that is enjoying increasing scientific and...

2008-08-04 03:00:07

WALTHAM, Mass., Aug. 4, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter ended June 30, 2008 and presented an update on recent clinical and corporate progress. Financial Results The Company reported a net loss for the second quarter of 2008 of $7.0 million, or $0.25 per share, compared with a net loss of $5.4 million,...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin